Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 26261259

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2015 Nov 10
First author
Modest DP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2015 Nov 10;33(32):3686-8. doi: 10.1200/JCO.2015.62.8495.
    note
    Source null
    related pmid
    26324365
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2016 May 1;34(13):1565-6. doi: 10.1200/JCO.2015.66.3799.
    note
    Source null
    related pmid
    26951313
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2016 May 1;34(13):1563-4. doi: 10.1200/JCO.2015.65.9086.
    note
    Source null
    related pmid
    26951319
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2016 May 1;34(13):1564. doi: 10.1200/JCO.2015.66.1512.
    note
    Source null
    related pmid
    26951321
    relationship
    Comment in

Authors and identifiers

  1. name
    Modest DP
    type
    Author
  2. name
    Stintzing S
    type
    Author
  3. name
    von Weikersthal LF
    type
    Author
  4. name
    Decker T
    type
    Author
  5. name
    Kiani A
    type
    Author
  6. name
    Vehling-Kaiser U
    type
    Author
  7. name
    Al-Batran SE
    type
    Author
  8. name
    Heintges T
    type
    Author
  9. name
    Lerchenmüller C
    type
    Author
  10. name
    Kahl C
    type
    Author
  11. name
    Seipelt G
    type
    Author
  12. name
    Kullmann F
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Modest DP
    type
    Author
  2. name
    Stintzing S
    type
    Author
  3. name
    von Weikersthal LF
    type
    Author
  4. name
    Decker T
    type
    Author
  5. name
    Kiani A
    type
    Author
  6. name
    Vehling-Kaiser U
    type
    Author
  7. name
    Al-Batran SE
    type
    Author
  8. name
    Heintges T
    type
    Author
  9. name
    Lerchenmüller C
    type
    Author
  10. name
    Kahl C
    type
    Author
  11. name
    Seipelt G
    type
    Author
  12. name
    Kullmann F
    type
    Author
bibliography ids
  1. nci-bib-3f7c11cf5b31e895c872692d
book metadata
content sha256
6daad48df935d89e51143c98e952065a05694ca64d7b68f98aa7f0ef626ffb0a
document type
citation
dois
  1. 10.1200/JCO.2015.61.2887
electronic publication date
display
2015 Aug 10
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26261259
immutable id
pubmed:26261259@6daad48df935d89e51143c98e952065a05694ca64d7b68f98aa7f0ef626ffb0a
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
32
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3718-26
volume
33
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2015 Nov 10;33(32):3686-8. doi: 10.1200/JCO.2015.62.8495.
    note
    Source null
    related pmid
    26324365
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2016 May 1;34(13):1565-6. doi: 10.1200/JCO.2015.66.3799.
    note
    Source null
    related pmid
    26951313
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2016 May 1;34(13):1563-4. doi: 10.1200/JCO.2015.65.9086.
    note
    Source null
    related pmid
    26951319
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2016 May 1;34(13):1564. doi: 10.1200/JCO.2015.66.1512.
    note
    Source null
    related pmid
    26951321
    relationship
    Comment in
outcomes validated
false
pmid
26261259
provenance
batch id
4c1ece5bfc3d8e2be622
provider
NCBI PubMed ESummary
record sha256
64186cf2d543a1135825e67bde75fad85072d3d7aa37556cc5ed28dd152e8af8
response sha256
85f81bf7b60c457e4b5806b47c7c67c745ada2ae114069aa45de5ef977770dba
retrieved at
2026-09-09T23:47:12.730551+00:00
publication date
display
2015 Nov 10
precision
day
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26261259/
title
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

Preserved source evidence · Independent clinical review pending · Not medical advice